Guardant Health set 2026 guidance forecasting a major ramp in Shield screening volumes and disclosed the acquisition of MetaSight Diagnostics to expand its cancer screening portfolio. Executives said Shield volumes should rise sequentially every quarter in 2026 and guided screening revenue to $162–$174 million, citing adoption by primary care and partnerships with diagnostic networks. Guardant also paid $59 million upfront to acquire MetaSight and up to $90 million of contingent consideration tied to regulatory and commercial milestones. Management framed the moves as doubling down on blood‑based screening amid intensifying competition in early detection.